Literature DB >> 1383346

Use of anti-peptide antibodies for the design of antigen-specific immune complex assays.

T Maruyama1, G B Thornton, S Iino, K Kurokawa, D R Milich.   

Abstract

A simple and sensitive method is described for the detection of circulating immune complexes (ICs) in an antigen-specific manner. The method is based on the use of anti-peptide antibodies as solid-phase capture reagents to bind antigen which is complexed to serum antibodies. The bound serum antibody is detected with a labelled second antibody. The method requires that the anti-peptide antibodies bind native protein efficiently, and that the anti-peptide antibodies do not compete with antibodies raised against the native protein which are involved in IC formation. Two anti-peptide antibodies specific for the hepatitis B surface antigen (HBsAg) and the hepatitis B e antigen (HBeAg), which possessed the requisite characteristics, were chosen as models for IC assay development. The solid-phase, anti-peptide based assays efficiently detected HBsAg and HBeAg-containing ICs in preformed antigen/antibody mixtures and in the serum of chronically infected hepatitis B patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383346     DOI: 10.1016/0022-1759(92)90272-u

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

Review 1.  The humoral immune response in acute and chronic hepatitis B virus infection.

Authors:  D R Milich; M Sallberg; T Maruyama
Journal:  Springer Semin Immunopathol       Date:  1995

2.  The serology of chronic hepatitis B infection revisited.

Authors:  T Maruyama; A McLachlan; S Iino; K Koike; K Kurokawa; D R Milich
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

3.  Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon-gamma: abrogation of immune response defect to a T-cell-dependent antigen.

Authors:  S M Akbar; K Inaba; M Onji
Journal:  Immunology       Date:  1996-04       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.